Cowen reiterated an Outperform rating and $368.00 price target on Biogen (NASDAQ: BIIB) following the company's 3Q15 earnings results. BIIB ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View

Leerink Partners Remains Bullish on Biogen (BIIB) Following 3Q Earnings Results October 21, 2015 1:42 PM Pre-Open Stock Movers 10/21: (KLAC) (ISRG) (SNDK) Higher; (SNTA) (VMW) (TWTR) Lower (more...)October 21, 2015 9:27 AM RBC Comments on Bull/Bear Case on Biogen (BIIB) Following Q3 ResultsOctober 21, 2015 9:22 AM Biogen to cut 11 percent of staff, cancel some drug programs; stock jumpsOctober 21, 2015 7:45 AM Biogen (BIIB) will resume trading at 8:00am ETOctober 21, 2015 7:40 AM Biogen's (BIIB) Phase 3 ASCEND Trial Missed Primary, Secondary EndpointsOctober 21, 2015 7:32 AM Biogen (BIIB) Tops Q3 EPS by 68c; Announces Corp. Restructuring; Boosts FY15 EPS OutlookOctober 21, 2015 7:31 AM Biogen Reports Top-Line Results from Phase 3 Study Evaluating Natalizumab in Secondary Progressive MSOctober 21, 2015 7:31 AM Biogen Third Quarter 2015 Revenues Increase 11% to $2.8 Billion; Company Raises 2015 Full Year GuidanceOctober 21, 2015 7:30 AM Biogen (BIIB) Halted, News PendingOctober 21, 2015 7:25 AM Trading Radar for 10/21: Coca Cola (KO), GM (GM), AmEx (AXP), Boeing (BA), Kimberly-Clark (KMB) ReportOctober 20, 2015 2:40 PM Biogen (BIIB) Bullish View Reiterated at Jefferies Following Sensitivity AnalysisOctober 20, 2015 7:12 AM